Loading...
•
Dec 31, 2024
Fulgent Q4 2024 Earnings Report
Fulgent's financial performance for Q4 2024 and full year results were reported.
Key Takeaways
Fulgent Genetics reported Q4 2024 revenue of $76.2 million, with core revenue growing 14% year-over-year to $76.0 million. The company experienced a GAAP loss of $5.9 million, or ($0.19) per share, but a non-GAAP income of $1.2 million, or $0.04 per share. They ended the year with $828.6 million in cash, cash equivalents, and investments.
Total Revenue reached $76.2 million.
Core Revenue grew 14% year-over-year to $76.0 million.
GAAP loss was reported at $5.9 million, or ($0.19) per share.
Non-GAAP income amounted to $1.2 million, or $0.04 per share.
Revenue by Segment
Forward Guidance
For the full year 2025, Fulgent expects core revenue of approximately $310 million, a GAAP loss of approximately ($1.95) per share, a non-GAAP loss of approximately ($0.65) per share, and cash, cash equivalents, and investments in marketable securities of approximately $780 million as of December 31, 2025.
Positive Outlook
- Core Revenue of approximately $310 million
- Cash, cash equivalents, and investments in marketable securities of approximately $780 million as of December 31, 2025
Challenges Ahead
- GAAP loss of approximately ($1.95) per share
- Non-GAAP loss of approximately ($0.65) per share
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...